MAPT and early-onset autosomal dominant Alzheimer disease: These findings were deemed less than satisfactory.[77] The development of tau protein-targeted therapies for Alzheimer’s disease is still predominantly in phase II clinical trials,[78] yet there is still considerable optimism regarding their potential to alter the course of the disease.